Literature DB >> 11151970

Micronized purified flavonoid fraction and the treatment of chronic venous insufficiency: microcirculatory mechanisms.

P D Smith1.   

Abstract

The standard treatments for venous diseases of the lower limb include compression bandaging and stockings as well as surgical removal of varicose veins. There is a number of conditions in which these conventional treatments are ineffective, particularly in the management of leg ulceration. Drug treatments for healing venous leg ulcers have yet to be developed to the stage of good clinical efficacy, but may assist in the management of patients. Flavonoid drugs have been widely used in the management of the symptoms of venous disease for many years and have recently been studied in some detail to assess their effects on the microcirculation. Work in animal models of ischemia/reperfusion (I/R) show that micronized purified flavonoid fraction (MPFF) modulates leukocyte adhesion and prevents endothelial damage. Similar biochemical effects have been observed in patients with venous disease and may explain the efficacy of this drug in the management of edema and other symptoms of venous disease. There is some evidence that MPFF promotes venous leg ulcer healing.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11151970

Source DB:  PubMed          Journal:  Microcirculation        ISSN: 1073-9688            Impact factor:   2.628


  2 in total

Review 1.  Cerebral venous collaterals: A new fort for fighting ischemic stroke?

Authors:  Lu-Sha Tong; Zhen-Ni Guo; Yi-Bo Ou; Yan-Nan Yu; Xiao-Cheng Zhang; Jiping Tang; John H Zhang; Min Lou
Journal:  Prog Neurobiol       Date:  2017-12-02       Impact factor: 11.685

Review 2.  Targeting Nitric Oxide with Natural Derived Compounds as a Therapeutic Strategy in Vascular Diseases.

Authors:  Maurizio Forte; Valeria Conti; Antonio Damato; Mariateresa Ambrosio; Annibale A Puca; Sebastiano Sciarretta; Giacomo Frati; Carmine Vecchione; Albino Carrizzo
Journal:  Oxid Med Cell Longev       Date:  2016-08-29       Impact factor: 6.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.